Jan. 10, 2018—Beckman Coulter Diagnostics announced the addition of 6-acetylmorphine and buprenorphine assays to its menu of drugs-of-abuse tests for use on Beckman Coulter’s scalable AU chemistry analyzer solutions (AU480, AU680, AU5800).
“Overdose with amphetamines requires a different treatment than opioid-related overdose. Therefore, providing hospitals and clinical laboratories with highly specific tests to distinguish between these two classes of drugs is important to ensure that patients receive appropriate care,” Michael Samoszuk, MD, chief medical officer of Beckman Coulter Diagnostics, said in a company statement.
The Syva Emit II Plus 6-AM assay provides a convenient and quick way to selectively screen for heroin usage, in place of time-consuming alternative methods like gas chromatography and mass spectrometry. The assay minimizes false-positives by demonstrating no cross-reactivity to morphine, morphine metabolites, and common analgesics.
The Syva Emit II Plus BUP assay is intended for use in laboratories for the qualitative and/or semiquantitative analysis of buprenorphine in human urine. The assay also minimizes false-positives due to its high specificity for buprenorphine and norbuprenorphine, with no cross-reactivity to commonly abused opiates. With a cutoff of 5 ng/mL, the BUP assay performs with improved sensitivity to minimize false-negative results as well.
Both assays deliver greater than 99 percent agreement with the reference method (GC/MS).